Cargando…
Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement
PURPOSE: Platelet rich plasma (PRP) is widely used in orthopaedics, but is still heavily debated. Therefore, a survey among the German “Working Group for Clinical Tissue Regeneration” of the German Society of Orthopaedics and Traumatology was conducted to achieve a consensus about the current therap...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471237/ https://www.ncbi.nlm.nih.gov/pubmed/32885339 http://dx.doi.org/10.1186/s40634-020-00282-2 |
_version_ | 1783578739591872512 |
---|---|
author | Tischer, T. Bode, G. Buhs, M. Marquass, B. Nehrer, S. Vogt, S. Zinser, W. Angele, P. Spahn, G. Welsch, G. H. Niemeyer, P. Madry, H. |
author_facet | Tischer, T. Bode, G. Buhs, M. Marquass, B. Nehrer, S. Vogt, S. Zinser, W. Angele, P. Spahn, G. Welsch, G. H. Niemeyer, P. Madry, H. |
author_sort | Tischer, T. |
collection | PubMed |
description | PURPOSE: Platelet rich plasma (PRP) is widely used in orthopaedics, but is still heavily debated. Therefore, a survey among the German “Working Group for Clinical Tissue Regeneration” of the German Society of Orthopaedics and Traumatology was conducted to achieve a consensus about the current therapeutical potential of PRP. METHODS: A first survey (n = 65 experts, all orthopaedic/trauma surgeons) was conducted (n = 13 questions). Following, a second round (n = 40 experts) was conducted with 31 questions to achieve consensus in 5 categories: three most common indications, PRP application, future research areas. RESULTS: Therapeutic PRP application was regarded as useful (89%), possibly even more important in the future (90%). Most common indications were tendon pathologies (77%), osteoarthritis (OA) (68%), muscle injuries (57%) and cartilage damage (51%). Consensus was reached in 16/31 statements. The application of PRP for early knee OA (Kellgren-Lawrence grade II) was regarded as potentially useful, as well as for acute and chronic tendinopathies. For chronic lesions (cartilage, tendons), multiple injections (2–4) were seen preferable to singular injections. However, no sufficient data exists on the time interval between the injections. Standardization of PRP preparation, application, frequency, as well as determining the range of indication is strongly recommended. CONCLUSIONS: There is a need of further standardization of the PRP preparation methods, indication and application protocols for knee OA and other indications, which must be further evaluated in basic science studies and randomized controlled clinical trials. LEVEL OF EVIDENCE: Consensus of expert opinion, Level V. |
format | Online Article Text |
id | pubmed-7471237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-74712372020-09-16 Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement Tischer, T. Bode, G. Buhs, M. Marquass, B. Nehrer, S. Vogt, S. Zinser, W. Angele, P. Spahn, G. Welsch, G. H. Niemeyer, P. Madry, H. J Exp Orthop Original Paper PURPOSE: Platelet rich plasma (PRP) is widely used in orthopaedics, but is still heavily debated. Therefore, a survey among the German “Working Group for Clinical Tissue Regeneration” of the German Society of Orthopaedics and Traumatology was conducted to achieve a consensus about the current therapeutical potential of PRP. METHODS: A first survey (n = 65 experts, all orthopaedic/trauma surgeons) was conducted (n = 13 questions). Following, a second round (n = 40 experts) was conducted with 31 questions to achieve consensus in 5 categories: three most common indications, PRP application, future research areas. RESULTS: Therapeutic PRP application was regarded as useful (89%), possibly even more important in the future (90%). Most common indications were tendon pathologies (77%), osteoarthritis (OA) (68%), muscle injuries (57%) and cartilage damage (51%). Consensus was reached in 16/31 statements. The application of PRP for early knee OA (Kellgren-Lawrence grade II) was regarded as potentially useful, as well as for acute and chronic tendinopathies. For chronic lesions (cartilage, tendons), multiple injections (2–4) were seen preferable to singular injections. However, no sufficient data exists on the time interval between the injections. Standardization of PRP preparation, application, frequency, as well as determining the range of indication is strongly recommended. CONCLUSIONS: There is a need of further standardization of the PRP preparation methods, indication and application protocols for knee OA and other indications, which must be further evaluated in basic science studies and randomized controlled clinical trials. LEVEL OF EVIDENCE: Consensus of expert opinion, Level V. Springer Berlin Heidelberg 2020-09-03 /pmc/articles/PMC7471237/ /pubmed/32885339 http://dx.doi.org/10.1186/s40634-020-00282-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Paper Tischer, T. Bode, G. Buhs, M. Marquass, B. Nehrer, S. Vogt, S. Zinser, W. Angele, P. Spahn, G. Welsch, G. H. Niemeyer, P. Madry, H. Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title | Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title_full | Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title_fullStr | Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title_full_unstemmed | Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title_short | Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage – German working group position statement |
title_sort | platelet-rich plasma (prp) as therapy for cartilage, tendon and muscle damage – german working group position statement |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471237/ https://www.ncbi.nlm.nih.gov/pubmed/32885339 http://dx.doi.org/10.1186/s40634-020-00282-2 |
work_keys_str_mv | AT tischert plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT bodeg plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT buhsm plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT marquassb plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT nehrers plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT vogts plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT zinserw plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT angelep plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT spahng plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT welschgh plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT niemeyerp plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement AT madryh plateletrichplasmaprpastherapyforcartilagetendonandmuscledamagegermanworkinggrouppositionstatement |